Vericel Announces Appointment of Michael Halpin as Senior Vice President, Quality and Regulatory Affairs
April 10 2017 - 9:20AM
Vericel Corporation (Nasdaq:VCEL), a leading developer of expanded
autologous cell therapies for the treatment of patients with
serious diseases and conditions, today announced the appointment of
Michael Halpin as senior vice president, quality and regulatory
affairs.
Mr. Halpin was formerly vice president, North American region
regulatory head at Sanofi Genzyme, with responsibility for Sanofi
Genzyme’s rare disease, immuno-inflammatory, multiple sclerosis and
other business unit products. Previously, Mr. Halpin served
as vice president, regulatory affairs for Genzyme’s biosurgery
division, with regulatory oversight of all biosurgery and cell and
gene therapy products, including Carticel®, Epicel®, and
MACI®. Prior to Genzyme, Mr. Halpin held a number of
regulatory, quality, and clinical affairs positions at several
medical device companies, including Abbott/MediSense, C.R. Bard,
and Abiomed. Mr. Halpin received his master’s degree in
biomedical engineering and bachelor’s degree in biochemistry from
the University of Virginia.
"Mike is a recognized global leader in the cell and gene therapy
regulatory field, and he brings tremendous experience in the
medical device field to Vericel," said Nick Colangelo, president
and chief executive officer of Vericel. "Mike’s deep knowledge of
our business and product portfolio will be extremely valuable to
the Company as we continue to execute on our regulatory, product
development and commercial strategies."
About Vericel CorporationVericel develops,
manufactures, and markets expanded autologous cell therapies for
the treatment of patients with serious diseases and
conditions. The company markets three cell therapy products
in the United States. Vericel is marketing MACI® (autologous
cultured chondrocytes on porcine collagen membrane), an autologous
cellularized scaffold product indicated for the repair of
symptomatic, single or multiple full-thickness cartilage defects of
the knee with or without bone involvement in adults.
Carticel® (autologous cultured chondrocytes) is an autologous
chondrocyte implant for the treatment of cartilage defects in the
knee in patients who have had an inadequate response to a prior
arthroscopic or other surgical repair procedure. Epicel®
(cultured epidermal autografts) is a permanent skin replacement for
the treatment of patients with deep dermal or full thickness burns
greater than or equal to 30% of total body surface area.
Vericel is also developing ixmyelocel-T, an autologous
multicellular therapy intended to treat advanced heart failure due
to ischemic dilated cardiomyopathy (DCM). For more
information, please visit the company's website at
www.vcel.com.
Epicel®, Carticel®, and MACI® are registered trademarks of
Vericel Corporation. © 2017 Vericel Corporation. All
rights reserved.
This document contains forward-looking statements, including,
without limitation, statements concerning anticipated progress,
objectives and expectations regarding the commercial potential of
our products, intended product development, clinical activity
timing, regulatory progress, and objectives and expectations
regarding our company described herein, all of which involve
certain risks and uncertainties. These statements are often, but
are not always, made through the use of words or phrases such as
"anticipates," "intends," "estimates," "plans," "expects," "we
believe," "we intend," and similar words or phrases, or future or
conditional verbs such as "will," "would," "should," "potential,"
"could," "may," or similar expressions. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the inherent uncertainties associated with
competitive developments, clinical trial and product development
activities, regulatory approval requirements, estimating the
commercial growth potential of our products and product candidates,
market demand for our products, and our ability to supply or meet
customer demand for our products. These and other significant
factors are discussed in greater detail in Vericel's Annual Report
on Form 10-K for the year ended December 31, 2016, filed with the
Securities and Exchange Commission ("SEC") on March 13, 2017,
Quarterly Reports on Form 10-Q and other filings with the SEC.
These forward-looking statements reflect management's current views
and Vericel does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release
except as required by law.
CONTACT:
Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
or
Lee Stern
The Trout Group
lstern@troutgroup.com
(646) 378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024